TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02412995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 1-2-3
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 1-3-2
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 2-3-1
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 2-1-3
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
Study: NCT02476773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel plus GLA-AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel plus GLA-AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel plus GLA-AF
Study: NCT02412995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 3-1-2
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
Study: NCT02476773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel plus GLA-AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel plus GLA-AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sterile Saline Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sterile Saline Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sterile Saline Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sterile Saline Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sterile Saline Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sterile Saline Placebo
Study: NCT03047590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-based Exercise Intensity
Description: Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-based Exercise Intensity
Description: Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Focus
Description: Participants are instructed to focus on feeling good while exercising.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Focus
Description: Participants are instructed to focus on feeling good while exercising.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate-based Exercise Intensity
Description: Participants are instructed to regulate their exercise intensity based on their heart rate.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate-based Exercise Intensity
Description: Participants are instructed to regulate their exercise intensity based on their heart rate.
Study: NCT02325050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
Study: NCT03514303

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spiriplex Allergenex Microassay
Description: A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
Study: NCT04126967

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS patients
Description: The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
Study: NCT02855346

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 200 mg of DPV + 320 mg LNG
Description: DPV VR, containing 200 mg DPV

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 200 mg of DPV
Description: DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
Study: NCT00610935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular injection
Study: NCT04628403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lasertherapy
Description: lasertherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock waves
Description: shock waves
Study: NCT03873467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance
Description: The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
Study: NCT01801137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Study: NCT05365620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical In-Line Inexsufflation
Description: In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter suction
Description: catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
Study: NCT03132805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATHS to PAX
Description: A universal classroom-based preventive intervention designed to prevent aggression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATHS to PAX and the Incredible Years
Description: A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
Study: NCT04708392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
Study: NCT03066791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin and Bioperine tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT03143517

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
Study: NCT04599621

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid
Description: Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
Study: NCT00883935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir 300 mg
Description: Atazanavir 300 mg once per day for 14 days in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg
Description: Atazanavir 400 mg once a day for 14 days in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg once a day for 14 days in Period 2
Study: NCT04904055

Intervention type: OTHER
Intervention: Value-based Formulary
Description: Prescription drug formulary tiers informed by estimated value
Study: NCT00666887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100 mg twice daily to be taken for up to 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo twice daily for 2 years
Study: NCT03754530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: orally three times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: orally three times per day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT or SRS
Description: \>3 with WBRT;\<=3 with SRS
Study: NCT04035382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labor induction
Description: The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
Study: NCT04282655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Guardian Milk Warmer (Medela TM)
Description: Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard warming procedure of breast milk in syringe prior to feeding.
Study: NCT01355302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7050
Description: E7050 given orally at either 200, 300, or 400 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: E7050 given orally at either 200, 300, or 400 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Study: NCT03471988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK1820
Description: Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend
Study: NCT00436917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: zoledronic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Letrozole as adjuvant therapy
Description: standard care
Study: NCT00074750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTGM
Description: Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
Study: NCT03282266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PADN
Description: PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
Study: NCT03346954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-Methionine PET/MRI
Description: Implementation \[11C\]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The \[11C\]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
Study: NCT04689893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Dotatate
Description: 68Ga-Dotatate was injected into the patients before the PET/CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-JR11
Description: 68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
Study: NCT00267163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00929058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intra-arterial infusion during 6 minutes
Study: NCT05917691

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
Study: NCT02412995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence 3-2-1
Description: The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
Study: NCT02325050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
Study: NCT05917691

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.

Intervention type: DRUG
Intervention: General anesthetic
Description: Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database).